» Articles » PMID: 35600848

Crosstalk of Histone and RNA Modifications Identified a Stromal-Activated Subtype with Poor Survival and Resistance to Immunotherapy in Gastric Cancer

Overview
Journal Front Pharmacol
Date 2022 May 23
PMID 35600848
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging evidence has revealed the pivotal role of epigenetic modifications in shaping the tumor microenvironment (TME). However, crosstalk between different modification types and their clinical relevance in cancers remain largely unexplored. In this study, using ChIP/MeRIP-seq data of seven human gastric cell lines, we systematically characterized the crosstalk of four epigenetic modification types including H3K4me1, H3K4me3, H3K27ac, and N6-methyladenosine (m6A) and identified a recurrent subtype with high FTO expression and low HDAC1 expression across three independent gastric cancer (GC) cohorts, which we named the epigenetic-modification-dysregulated (EMD) subtype. Patients of the EMD subtype were featured with poor survival, stromal activation, and immune suppression. Extensive relevance to clinical characteristics was observed in the EMD subtype, including the Lauren classification, MSI status, histological grade, TNM stage, the Asian Cancer Research Group classification, and the immune/fibrotic classification. An EMD score was then constructed using WGCNA and ssGSEA algorithms, to precisely recognize the EMD subtype and indicate prognosis and response to immunotherapy in multiple independent GC cohorts. Correlations of the EMD score with tumor mutation burden, tumor purity, aneuploidy score, tumorigenic pathways, TME characteristics, and FTO/HDAC1 ratio were measured. experiments were performed to demonstrate the correlation between FTO and the epithelial-mesenchymal transition pathway, which suggested FTO as a targetable vulnerability for GC patients with a high EMD score. Altogether, by comprehensively analyzing the epigenetic modification patterns of 1518 GC patients, we identified a novel stromal-activated subtype with poor survival and resistance to immunotherapy, which might benefit from the combined immune checkpoint inhibition therapy with FTO inhibition.

Citing Articles

Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies.

Luo D, Zhou J, Ruan S, Zhang B, Zhu H, Que Y Cell Death Dis. 2025; 16(1):75.

PMID: 39915459 PMC: 11803115. DOI: 10.1038/s41419-025-07385-7.


Genetic dysregulation of EP300 in cancers in light of cancer epigenome control - targeting of p300-proficient and -deficient cancers.

Gronkowska K, Robaszkiewicz A Mol Ther Oncol. 2024; 32(4):200871.

PMID: 39351073 PMC: 11440307. DOI: 10.1016/j.omton.2024.200871.


Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor.

Hung Y, Wang H, Pan M, Chen L J Pers Med. 2024; 14(3).

PMID: 38540967 PMC: 10971448. DOI: 10.3390/jpm14030224.


RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy.

Liu W, Zheng S, Li T, Fei Y, Wang C, Zhang S Signal Transduct Target Ther. 2024; 9(1):70.

PMID: 38531882 PMC: 10966055. DOI: 10.1038/s41392-024-01777-5.


Epigenetic modifications: Key players in cancer heterogeneity and drug resistance.

Sadida H, Abdulla A, Al Marzooqi S, Hashem S, Macha M, Akil A Transl Oncol. 2023; 39:101821.

PMID: 37931371 PMC: 10654239. DOI: 10.1016/j.tranon.2023.101821.


References
1.
Tao L, Mu X, Chen H, Jin D, Zhang R, Zhao Y . FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med. 2021; 11(2):e310. PMC: 7851431. DOI: 10.1002/ctm2.310. View

2.
Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

3.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

4.
Meng Q, Lu Y, Ruan D, Yu K, Chen Y, Xiao M . DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. Mol Ther Nucleic Acids. 2021; 24:695-710. PMC: 8099484. DOI: 10.1016/j.omtn.2021.03.023. View

5.
Zhao Y, Chen Y, Jin M, Wang J . The crosstalk between mA RNA methylation and other epigenetic regulators: a novel perspective in epigenetic remodeling. Theranostics. 2021; 11(9):4549-4566. PMC: 7977459. DOI: 10.7150/thno.54967. View